Physician profile
Carl Fastabend
NPI 1568438984
$186,100.20
in general payments reported to CMS, 2019-2025
16 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $26K · 2021: $23K · 2022: $14K · 2023: $15K · 2024: $14K · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,950 · Food and Beverage: $2,514 · Honoraria: $800 · Travel and Lodging: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,208.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,950.00 |
| Food and Beverage | $2,513.53 |
| Honoraria | $800.00 |
| Travel and Lodging | $719.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $136,256.66 | 2019-2025 | (9520) Igt Devices Undivided, (6554) Periph Vasc Undiv, Igt Devices Undivided |
| Medtronic, INC. | $32,877.89 | 2021-2025 | Venaseal, Abre, Endurant Iis |
| Provisio Medical, INC. | $11,218.74 | 2022-2023 | |
| Bard Peripheral Vascular, INC. | $3,461.53 | 2019-2021 | |
| Medtronic Vascular, INC. | $852.23 | 2019-2020 | |
| Pfizer INC. | $535.00 | 2019-2023 | |
| Inari Medical, INC. | $280.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $146.67 | 2019-2022 | |
| Abbott Laboratories | $136.49 | 2019 | |
| Biosense Webster, INC. | $120.00 | 2019 | |
| Heartflow, INC. | $93.73 | 2022 | |
| Boston Scientific Corporation | $54.85 | 2023-2024 | Watchman Flx, Varithena Administration Pack |
| Organogenesis INC. | $27.01 | 2023 | Puraply |
| Cardiovascular Systems INC. | $26.65 | 2019 | |
| Biocompatibles, INC. | $11.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$193,575.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Fastabend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.